Drug Information Center (DIC)
Anastrozole Management Post-Stroke
Should anastrozole be stopped after an ischemic stroke?
✘ No automatic discontinuation.
Management requires individualized risk-benefit assessment after acute stabilization.
| Source | Position |
|---|---|
| NCCN/ASCO | No recommendation to routinely stop aromatase inhibitors post-stroke |
| AHA/ASA | Acute ischemic stroke management unchanged by cancer or AI use |
| Thrombolysis | Active cancer or endocrine therapy is not a contraindication |
Overall Evidence Strength: Moderate - Conflicting
| Comparison | Key Finding |
|---|---|
| AIs vs Tamoxifen | ↑ ischemic stroke risk ($OR \approx 1.3-1.4$) |
| AIs vs Non-use (large cohort) | ☑ No clinically significant ↑ MACE |
| Lipid effects | ↑ LDL, ↑ total cholesterol (atherogenic profile) |
Interpretation: Risk signal exists relative to tamoxifen, but not consistently elevated versus baseline cardiovascular risk.
- Proceed with standard AIS protocol (imaging → IV alteplase / thrombectomy if eligible)
- Do not interrupt anastrozole acutely
- Delay reperfusion therapy
- Stop endocrine therapy reflexively during acute management
Factors Favoring Continuation
- High oncologic recurrence risk
- Contraindication to tamoxifen (e.g., prior VTE, endometrial disease)
- Clear, treatable stroke etiology (e.g., AF now anticoagulated)
Factors Favoring Discontinuation / Switch
- High risk of recurrent or disabling stroke
- Low oncologic risk or near completion of AI course
- Acceptable candidacy for tamoxifen (with VTE risk acknowledged)
Mandatory Measures:
- High-intensity statin therapy
- Strict BP and glycemic control
- Guideline-directed antiplatelet or anticoagulation
- Lipid monitoring
- Multidisciplinary follow-up (oncology + neurology ± cardiology)
- Do not stop anastrozole automatically after ischemic stroke
- Acute stroke care has absolute priority
- Long-term decision should be multidisciplinary, patient-centered, and risk-stratified
Drug Information Center (DIC)
Anastrozole Management Post-Stroke
Should anastrozole be stopped after an ischemic stroke?
✘ No automatic discontinuation.
Management requires individualized risk-benefit assessment after acute stabilization.
| Source | Position |
|---|---|
| NCCN/ASCO | No recommendation to routinely stop aromatase inhibitors post-stroke |
| AHA/ASA | Acute ischemic stroke management unchanged by cancer or AI use |
| Thrombolysis | Active cancer or endocrine therapy is not a contraindication |
Overall Evidence Strength: Moderate - Conflicting
| Comparison | Key Finding |
|---|---|
| AIs vs Tamoxifen | ↑ ischemic stroke risk ($OR \approx 1.3-1.4$) |
| AIs vs Non-use (large cohort) | ☑ No clinically significant ↑ MACE |
| Lipid effects | ↑ LDL, ↑ total cholesterol (atherogenic profile) |
Interpretation: Risk signal exists relative to tamoxifen, but not consistently elevated versus baseline cardiovascular risk.
- Proceed with standard AIS protocol (imaging → IV alteplase / thrombectomy if eligible)
- Do not interrupt anastrozole acutely
- Delay reperfusion therapy
- Stop endocrine therapy reflexively during acute management
Factors Favoring Continuation
- High oncologic recurrence risk
- Contraindication to tamoxifen (e.g., prior VTE, endometrial disease)
- Clear, treatable stroke etiology (e.g., AF now anticoagulated)
Factors Favoring Discontinuation / Switch
- High risk of recurrent or disabling stroke
- Low oncologic risk or near completion of AI course
- Acceptable candidacy for tamoxifen (with VTE risk acknowledged)
Mandatory Measures:
- High-intensity statin therapy
- Strict BP and glycemic control
- Guideline-directed antiplatelet or anticoagulation
- Lipid monitoring
- Multidisciplinary follow-up (oncology + neurology ± cardiology)
- Do not stop anastrozole automatically after ischemic stroke
- Acute stroke care has absolute priority
- Long-term decision should be multidisciplinary, patient-centered, and risk-stratified